Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

This is a phase 3 open label, multi-center, randomized, active-controlled non-inferiority trial that compares the safety and effectiveness of a 6-week regimen of daily rifapentine against the current standard of 12-16 weeks of rifamycin-based treatment for latent TB infection (LTBI).

The George Washington University is seeking volunteers for a LTBI clinical trial who are:

  • 18 years and older and living in the DC metro area
  • Require treatment of LTBI and are at increased risk of progression to tuberculosis

More information regarding the study can be found at


The Centers for Disease Control and Prevention (CDC),
Tuberculosis Trials Consortium (TBTC)
Principal Investigator(s)
Dr. Afsoon Roberts,
Dr. Jose Lucar
Contact Phone Number
Request Information
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.